{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:48:46Z","timestamp":1792705726615,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"am","delay-in-days":312,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007726","name":"Astrophysics Science Division","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007726","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.yebeh.2024.110183","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T05:41:50Z","timestamp":1733809310000},"page":"110183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Evaluating the patient needs and tolerability of Clobazam liquid formulation (Likozam\u00ae 1\u00a0mg\/mL): A French patient and care-givers\u2019 centered survey"],"prefix":"10.1016","volume":"163","author":[{"given":"Giovanna","family":"Scorrano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Delattre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Emmanuel","family":"Leiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rima","family":"Nabbout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2024.110183_b0005","unstructured":"Frisium (clobazam). Summary of product characteristics. https:\/\/www.medicines.org.uk\/emc\/product\/1574\/smpc#gref. Accessed 29 Aug 2022. n.d."},{"key":"10.1016\/j.yebeh.2024.110183_b0010","unstructured":"ONFI (clobazam). Prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/203993s005lbl.pdf. Accessed 29 Aug 2022. n.d."},{"key":"10.1016\/j.yebeh.2024.110183_b0015","unstructured":"European Medicines Agency (EMA). Clobazam: List of nationally authorised medicinal products - PSUSA\/00000798\/202002 Reference Number: EMA\/521021\/2020 n.d."},{"key":"10.1016\/j.yebeh.2024.110183_b0020","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s40263-022-00955-9","article-title":"Psychobehavioural and cognitive adverse events of anti-seizure medications for the treatment of developmental and epileptic encephalopathies","volume":"36","author":"Strzelczyk","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2024.110183_b0025","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1212\/WNL.0b013e318232de76","article-title":"Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome","volume":"77","author":"Ng","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2024.110183_b0030","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/j.1528-1167.2008.01935.x","article-title":"Clobazam in the treatment of Lennox\u2010Gastaut syndrome","volume":"50","author":"Conry","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2024.110183_b0035","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/epi.12561","article-title":"Stable dosages of clobazam for L ennox\u2010 G astaut syndrome are associated with sustained drop\u2010seizure and total\u2010seizure improvements over 3 years","volume":"55","author":"Conry","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2024.110183_b0040","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/archneur.1986.00520080064023","article-title":"Clobazam for refractory focal epilepsy: A controlled trial","volume":"43","author":"Schmidt","year":"1986","journal-title":"Arch Neurol"},{"key":"10.1016\/j.yebeh.2024.110183_b0045","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1528-1157.1987.tb03678.x","article-title":"Clobazam in therapy\u2010resistant patients with partial epilepsy: A double\u2010blind placebo\u2010controlled crossover study","volume":"28","author":"Koeppen","year":"1987","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2024.110183_b0050","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1136\/bmj.286.6373.1246","article-title":"Clobazam as adjunctive treatment in refractory epilepsy","volume":"286","author":"Allen","year":"1983","journal-title":"BMJ"},{"key":"10.1016\/j.yebeh.2024.110183_b0055","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1017\/S0317167100030651","article-title":"Clobazam as an add-on drug in the treatment of refractory epilepsy of childhood","volume":"17","author":"Keene","year":"1990","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.yebeh.2024.110183_b0060","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.eplepsyres.2012.10.010","article-title":"Clobazam therapy of refractory epilepsy in tuberous sclerosis complex","volume":"104","author":"Jennesson","year":"2013","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2024.110183_b0065","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/cns.12399","article-title":"Clobazam: A safe, efficacious, and newly rediscovered therapeutic for epilepsy","volume":"21","author":"Gauthier","year":"2015","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.yebeh.2024.110183_b0070","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/jcph.1313","article-title":"A comprehensive overview of the clinical pharmacokinetics of Clobazam","volume":"59","author":"Tolbert","year":"2019","journal-title":"J Clin Pharma"},{"key":"10.1016\/j.yebeh.2024.110183_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2019.106459","article-title":"Drug-drug interactions and pharmacodynamics of concomitant clobazam and cannabidiol or stiripentol in refractory seizures","volume":"99","author":"Klein","year":"2019","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2024.110183_b0080","unstructured":"Epaclob\/SilocalmTM (clobazam oral suspension). Full prescribing information. Essex, UK: Martindale Pharmaceuticals Limited; 2016. n.d."},{"key":"10.1016\/j.yebeh.2024.110183_b0085","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1111\/epi.17262","article-title":"Introduction to the epilepsy syndrome papers","volume":"63","author":"Wirrell","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2024.110183_b0090","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2024.110183_b0095","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/epi.13670","article-title":"Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Fisher","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2024.110183_b0100","unstructured":"European Medicines Agency (EMA). Guideline on pharmaceutical development of medicines for paediatric use EMA\/CHMP\/QWP\/805880\/2012 Rev. 2 n.d."},{"key":"10.1016\/j.yebeh.2024.110183_b0105","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.yebeh.2018.03.013","article-title":"Off-label use and manipulations of antiepileptic drugs in children: Analysis of the outpatient prescriptions in a tertiary center","volume":"82","author":"Kuchenbuch","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2024.110183_b0110","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1080\/14740338.2021.1890025","article-title":"Safety considerations selecting antiseizure medications for the treatment of individuals with Dravet syndrome","volume":"20","author":"Nabbout","year":"2021","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.yebeh.2024.110183_b0115","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-formulations-choice-paediatric-population_en.pdf. Committee for Human Medicinal Products (CHMP). Reflection paper: Formulations of choice for the paediatric population. EMEA\/CHMP\/PEG\/194810\/2005. 2006 Sep. Accessed March 15, 2021. n.d."},{"key":"10.1016\/j.yebeh.2024.110183_b0120","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1111\/bcp.15293","article-title":"From paediatric formulations development to access: Advances made and remaining challenges","volume":"88","author":"Litalien","year":"2022","journal-title":"Br J Clin Pharma"},{"key":"10.1016\/j.yebeh.2024.110183_b0125","doi-asserted-by":"crossref","unstructured":"How to identify and manage \u2018problem\u2019 excipients in medicines for children. Pharmaceutical Journal 2017. Doi: 10.1211\/PJ.2017.20203121.","DOI":"10.1211\/PJ.2017.20203121"},{"key":"10.1016\/j.yebeh.2024.110183_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107094","article-title":"Impact of childhood Dravet syndrome on care givers of patients with DS, a major impact on mothers","volume":"108","author":"Nabbout","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2024.110183_b0135","first-page":"57","article-title":"Impact of COVID-19 on Spanish patients with Dravet syndrome and their caregivers: Consequences of lockdown","volume":"73","author":"Cardenal-Mu\u00f1oz","year":"2021","journal-title":"Rev Neurol"},{"key":"10.1016\/j.yebeh.2024.110183_b0140","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/epi4.12464","article-title":"Impact of the COVID-19 lockdown on patients and families with Dravet syndrome","volume":"6","author":"Brambilla","year":"2021","journal-title":"Epilepsia Open"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505024005651?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505024005651?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:44:05Z","timestamp":1762548245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505024005651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":28,"alternative-id":["S1525505024005651"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2024.110183","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating the patient needs and tolerability of Clobazam liquid formulation (Likozam\u00ae 1\u00a0mg\/mL): A French patient and care-givers\u2019 centered survey","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2024.110183","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110183"}}